These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

134 related articles for article (PubMed ID: 24357849)

  • 21. Rare coding variants and breast cancer risk: evaluation of susceptibility Loci identified in genome-wide association studies.
    Zhang Y; Long J; Lu W; Shu XO; Cai Q; Zheng Y; Li C; Li B; Gao YT; Zheng W
    Cancer Epidemiol Biomarkers Prev; 2014 Apr; 23(4):622-8. PubMed ID: 24470074
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Germline variants in familial pituitary tumour syndrome genes are common in young patients and families with additional endocrine tumours.
    De Sousa SMC; McCabe MJ; Wu K; Roscioli T; Gayevskiy V; Brook K; Rawlings L; Scott HS; Thompson TJ; Earls P; Gill AJ; Cowley MJ; Dinger ME; McCormack AI
    Eur J Endocrinol; 2017 May; 176(5):635-644. PubMed ID: 28220018
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Genomic Biomarkers for Breast Cancer Risk.
    Walsh MF; Nathanson KL; Couch FJ; Offit K
    Adv Exp Med Biol; 2016; 882():1-32. PubMed ID: 26987529
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Assessment of rare BRCA1 and BRCA2 variants of unknown significance using hierarchical modeling.
    Capanu M; Concannon P; Haile RW; Bernstein L; Malone KE; Lynch CF; Liang X; Teraoka SN; Diep AT; Thomas DC; Bernstein JL; ; Begg CB
    Genet Epidemiol; 2011 Jul; 35(5):389-97. PubMed ID: 21520273
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Combined annotation-dependent depletion score for BRCA1/2 variants in patients with breast and/or ovarian cancer.
    Nakagomi H; Mochizuki H; Inoue M; Hirotsu Y; Amemiya K; Sakamoto I; Nakagomi S; Kubota T; Omata M
    Cancer Sci; 2018 Feb; 109(2):453-461. PubMed ID: 29215753
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Genetic counselling and testing of susceptibility genes for therapeutic decision-making in breast cancer-an European consensus statement and expert recommendations.
    Singer CF; Balmaña J; Bürki N; Delaloge S; Filieri ME; Gerdes AM; Grindedal EM; Han S; Johansson O; Kaufman B; Krajc M; Loman N; Olah E; Paluch-Shimon S; Plavetic ND; Pohlodek K; Rhiem K; Teixeira M; Evans DG
    Eur J Cancer; 2019 Jan; 106():54-60. PubMed ID: 30471648
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeted capture and massively parallel sequencing of 12 human exomes.
    Ng SB; Turner EH; Robertson PD; Flygare SD; Bigham AW; Lee C; Shaffer T; Wong M; Bhattacharjee A; Eichler EE; Bamshad M; Nickerson DA; Shendure J
    Nature; 2009 Sep; 461(7261):272-6. PubMed ID: 19684571
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Gene panel screening for insight towards breast cancer susceptibility in different ethnicities.
    Bishop MR; Omeler-Fenaud SM; Huskey ALW; Merner ND
    PLoS One; 2020; 15(8):e0238295. PubMed ID: 32866190
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tumor characteristics as an analytic tool for classifying genetic variants of uncertain clinical significance.
    Hofstra RM; Spurdle AB; Eccles D; Foulkes WD; de Wind N; Hoogerbrugge N; Hogervorst FB;
    Hum Mutat; 2008 Nov; 29(11):1292-303. PubMed ID: 18951447
    [TBL] [Abstract][Full Text] [Related]  

  • 30. BioBin: a bioinformatics tool for automating the binning of rare variants using publicly available biological knowledge.
    Moore CB; Wallace JR; Frase AT; Pendergrass SA; Ritchie MD
    BMC Med Genomics; 2013; 6 Suppl 2(Suppl 2):S6. PubMed ID: 23819467
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Strong functional data for pathogenicity or neutrality classify BRCA2 DNA-binding-domain variants of uncertain significance.
    Richardson ME; Hu C; Lee KY; LaDuca H; Fulk K; Durda KM; Deckman AM; Goldgar DE; Monteiro ANA; Gnanaolivu R; Hart SN; Polley EC; Chao E; Pesaran T; Couch FJ
    Am J Hum Genet; 2021 Mar; 108(3):458-468. PubMed ID: 33609447
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Robust and Powerful Affected Sibpair Test for Rare Variant Association.
    Lin KH; Zöllner S
    Genet Epidemiol; 2015 Jul; 39(5):325-33. PubMed ID: 25966809
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rare missense mutations in RECQL and POLG associate with inherited predisposition to breast cancer.
    Tervasmäki A; Mantere T; Hartikainen JM; Kauppila S; Lee HM; Koivuluoma S; Grip M; Karihtala P; Jukkola-Vuorinen A; Mannermaa A; Winqvist R; Pylkäs K
    Int J Cancer; 2018 Jun; 142(11):2286-2292. PubMed ID: 29341116
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A method to assess the clinical significance of unclassified variants in the BRCA1 and BRCA2 genes based on cancer family history.
    Gómez García EB; Oosterwijk JC; Timmermans M; van Asperen CJ; Hogervorst FB; Hoogerbrugge N; Oldenburg R; Verhoef S; Dommering CJ; Ausems MG; van Os TA; van der Hout AH; Ligtenberg M; van den Ouweland A; van der Luijt RB; Wijnen JT; Gille JJ; Lindsey PJ; Devilee P; Blok MJ; Vreeswijk MP
    Breast Cancer Res; 2009; 11(1):R8. PubMed ID: 19200354
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comprehensive analysis of NuMA variation in breast cancer.
    Kilpivaara O; Rantanen M; Tamminen A; Aittomäki K; Blomqvist C; Nevanlinna H
    BMC Cancer; 2008 Mar; 8():71. PubMed ID: 18331640
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value.
    Marisa L; de Reyniès A; Duval A; Selves J; Gaub MP; Vescovo L; Etienne-Grimaldi MC; Schiappa R; Guenot D; Ayadi M; Kirzin S; Chazal M; Fléjou JF; Benchimol D; Berger A; Lagarde A; Pencreach E; Piard F; Elias D; Parc Y; Olschwang S; Milano G; Laurent-Puig P; Boige V
    PLoS Med; 2013; 10(5):e1001453. PubMed ID: 23700391
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Rare genetic variants and the risk of cancer.
    Bodmer W; Tomlinson I
    Curr Opin Genet Dev; 2010 Jun; 20(3):262-7. PubMed ID: 20554195
    [TBL] [Abstract][Full Text] [Related]  

  • 38. BRCA1 and BRCA2 genetic testing-pitfalls and recommendations for managing variants of uncertain clinical significance.
    Eccles DM; Mitchell G; Monteiro AN; Schmutzler R; Couch FJ; Spurdle AB; Gómez-García EB;
    Ann Oncol; 2015 Oct; 26(10):2057-65. PubMed ID: 26153499
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The impact of rare and low-frequency genetic variants in common variable immunodeficiency (CVID).
    Bisgin A; Sonmezler O; Boga I; Yilmaz M
    Sci Rep; 2021 Apr; 11(1):8308. PubMed ID: 33859323
    [TBL] [Abstract][Full Text] [Related]  

  • 40. BRCA1 and BRCA2 unclassified variants and missense polymorphisms in Algerian breast/ovarian cancer families.
    Cherbal F; Salhi N; Bakour R; Adane S; Boualga K; Maillet P
    Dis Markers; 2012; 32(6):343-53. PubMed ID: 22684231
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.